Table 5.

Number (percentage and 95% confidence interval) of subjects with hemagglutination inhibition ≥1:330 (per-protocol set)

	Cohort 1 (9–17 years)		Cohort 2 (3–8 years)			Cohort 3 (1–<3 years)			Cohort 4 (6–11 months)
	3.75 μg +halfM F59 (n = 72 )	7.5 μg +fullM F59 (n = 71 )	3.75 μg +halfM F59 (n = 58 )	7.5 μg +fullM F59 (n = 60 )	15 μg +noM F59 (n = 31 )	3.75 μg +halfM F59 (n = 51 )	7.5 μg +fullM F59 (n = 53 )	15 μg +noM F59 (n = 25 )	3.75 μg +halfM F59 (n = 58 )	7.5 μg +fullM F59 (n = 54 )
Day 1	1 (1) (0.035–7)	0 (0) (0–5)	0 (0) (0–6)	0 (0) (0–6)	0 (0) (0–11)	3 (6) (1–16)	4 (8) (2–18)	3 (12) (3–31)	4 (7) (2–17)	4 (7) (2–18)
Day 22	10 (14) (7–24)	13 (18) (10–29)	2 (3) (0–12)	2 (3) (0–12)	2 (6) (1–21)	6 (12) (4–24)	7 (13) (5–25)	5 (20) (7–41)	11 (19) (10–31)	10 (19) (9–31)
Day 43	37 (51) (39–63)	35 (49) (37–61)	37 (64) (50–76)	41 (68) (55–80)	3 (10) (2–26)	38 (75) (60–86)	50 (94) (84–99)	6 (24) (9–45)	41 (71) (57–82)	45 (83) (71–92)
Pre-booster	n = 21	n = 22	n = 24	n = 31	n = 11	n = 36	n = 41	n = 19	n = 52	n = 46
Day 366	4 (19) (5–42)	5 (23) (8–45)	1 (4) (0–21)	4 (13) (4–30)	0 (0) (0–28)	5 (14) (5–29)	10 (24) (12–40)	4 (21)
(6–46)	13 (25) (14–39)	17 (37) (23–52)
Post-booster	n = 19	n = 20	n = 20	n = 29	n = 10	n = 32	n = 38	n = 17	n = 47	n = 40
Day 387	18 (95) (74–100)	19 (95) (75–100)	20 (100) (83–100)	29 (100) (88–100)	9 (90) (55–100)	30 (94) (79–99)	38 (100) (91–100)	16 (94) (71–100)	47 (100) (92–100)	40 (100) (91–100)